Overview

Efficacy and Tolerability of Xalatan in Patients

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Ophthalmic Solutions
Tetrahydrozoline